MY ACCOUNT | NEWSLETTER |

Seek Labs Maps Foot-and-Mouth Disease with BioSeeker™ to Advance Development of a Pan-Target, Programmable Therapeutic


Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the inclusion of Foot-and-Mouth Disease (FMD) in its BioSeeker™ Global Disease Atlas, advancing the company’s mission to transform genomic data at scale into programmable, CRISPR-based therapeutics. This expansion highlights BioSeeker’s ability to map high-priority veterinary pathogens and accelerate the development of countermeasures for diseases that destabilize food production, disrupt protein supply chains, and strain economic resilience.

FMD is one of the world’s most contagious livestock diseases, affecting cattle, pigs, sheep, goats, deer, elk, and bison. Outbreaks cause billions in losses through culling, trade restrictions, and market instability. Despite decades of control efforts, FMD remains endemic across Asia, Africa, the Middle East, and South America, with sporadic outbreaks continuing elsewhere. Earlier this year, an FMD-related outbreak in Germany—its first since 1988—spread rapidly into Hungary and Slovakia, the speed at which this virus can quickly spread and upend economic and operational infrastructure in countries where mitigation efforts have previously been successful.

Mapping FMD Weak Points with BioSeeker™

Foot-and-Mouth Disease presents a persistent challenge because vaccines must be tailored to regionally circulating strains, with efficacy dependent on timely surveillance and accurate strain matching. In many countries, surveillance is limited, and vaccine selection can be inconsistent, leaving gaps that allow outbreaks to spread and destabilize food systems.

BioSeeker™ addresses this challenge by scanning thousands of viral genomes across strains to identify conserved, high-value regions essential for viral survival across all known serotypes (O, A, C, Asia 1, SAT 1, SAT 2, and SAT 3). These “genomic vulnerabilities” are designed to remain therapeutically relevant even as the virus evolves, helping to reduce the risk of resistance seen with more broad-use small molecule antivirals. These mapped targets form the blueprint for Seek Labs’ Programmable Target Ablation Platform (PTAP™), which harnesses CRISPR systems to seek and destroy pathogens with genomic precision. By bringing FMD into the Atlas, BioSeeker compresses years of traditional discovery into weeks and lays the foundation for programmable, pathogen-specific therapeutics that could complement vaccines and strengthen global countermeasures.

“Protein supply chains are critical to global health, and transboundary diseases like FMD remind us how fragile they remain,” said Jared Bauer, CEO of Seek Labs. “By adding Foot-and-Mouth Disease to the Global Disease Atlas, we’re providing government and industry stakeholders alike with the genomic intelligence needed to strengthen and safeguard food systems and accelerate the next generation of programmable therapeutics.”

A Global Call to Advance Programmable Therapeutics for FMD

FMD joins African Swine Fever Virus (ASFV), Capripox (Lumpy Skin Disease, Sheep Pox, Goat Pox), and Classical Swine Fever (CSFV) in the Global Disease Atlas, representing high-priority threats to livestock, trade, and protein access. With FMD now integrated, Seek Labs reinforces its commitment to addressing both human and veterinary diseases that destabilize health systems and economies. The company is actively seeking creative collaborators and development partners across animal health, government, and pharma to help advance a pan-targeting FMD candidate into a first-in-class therapeutic.

About Seek Labs

At Seek Labs, we don’t wait for change—we build it. We’re pursuing the breakthroughs the world can’t wait for by developing programmable “seek-and-destroy” therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health.

Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with our partners, we’re building faster, smarter solutions for the world’s most urgent health challenges.


Source: www.seeklabs.com

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Penn Vet’s Wildlife Futures Seek to Unravel the Mystery of the Disappearing Barn Owl

Like0
Dislike0

NEL Animal Medical Foundation Brings K-Veterinary Excellence at ASASVC

Like0
Dislike0

Feline Mammary Hypertrophy/Fibroadenoma Complex: Clinical and Hormonal Aspects

Like0
Dislike0

Impact of Tumour Depth, Tumour Location and Multiple Synchronous Masses on the Prognosis of Canine Cutaneous Mast Cell Tumours

Like0
Dislike0

Prevention and Management of Surgical Pain in Cattle

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top